VINCENTMED：ANNUALRESULTSANNOUNCEMENTFORTHEYEARENDED31DECEMBER2025RECOMMENDATIONFORDECLARATIONOFFINALDIVIDENDANDCLOSUREOFREGISTEROFMEMBERS.pdf

1、1Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia

2、nce upon the whole or any part of the contents of this announcement.Vincent Medical Holdings Limited永 勝 醫 療 控 股 有 限 公 司(Incorporated in the Cayman Islands with limited liability)(Stock code:1612)ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2025,RECOMMENDATION FORDECLARATION OF FINAL DIV

3、IDENDANDCLOSURE OF REGISTER OF MEMBERSHIGHLIGHTS Revenue increased by 16.5%for the year ended 31 December 2025(“2025”or the“Year”),reaching HK$932.8 million(2024:HK$801.0 million).Revenue from the imaging disposable products segment increased by 39.8%to HK$549.7 million,accounted for 58.9%(2024:49.1

4、%)of the Groups total revenue,attributable to the strengthened relationship and expanded business scale with a major customer.Supported by greater economies of scale through improved capacity utilisation and operating efficiency,gross profit margin improved from 32.5%to 35.1%.Profit for the year inc

5、reased by 52.8%to HK$108.4 million(2024:HK$70.9 million).Net profit margin increased to 11.6%(2024:8.9%).The new research and development(“R&D”)and production facility(the“New Production Facility”)in Kaiping City,Jiangmen City,Guangdong Province,the Peoples Republic of China(the“PRC”)continued to pr

6、ogress towards trial operations to commence during 2026,followed by phased commercialisation in the coming years.The Board has resolved to declare a final dividend of HK2.6 cents(2024:HK1.7 cents)per share for the Year.Together with an interim dividend of HK2.4 cents(2024:HK1.6 cents)per share,the t